Federal contract award
0002
IGF::OT::IGF - RESEARCH&DEVELOPMENT IN SUPPORT OF THE US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY (USAMMDA) FOR THE PERFORMANCE OF A PHASE I, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE LONG-TERM OPHTHALMIC SAFETY OF TAFENOQUINE VERSUS PLACEBO.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541712 |
| PSC | AJ53 — LIFE SCIENCES - ADVANCED DEVELOPMENT |
| Parent award / vehicle | W81XWH15D0037 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $24.2M |
| Current contract value | $24.2M |
| Potential contract value / ceiling | $24.2M |
| Start date | Mar 22, 2017 |
| Current end date | Jul 31, 2022 |
| Potential end date | Jul 31, 2022 |
| Latest award activity | Jan 23, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jan 23, 2026 | 22 | $6.1K | TAFENOQUINE CLINICAL TRIALS |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.